> From: "NCID/VBI Public Inquiries (CDC)" <dvbid@cdc.gov>
> Date: April 13, 2021 at 8:00:04 PM EDT
> To: [redacted]
> Subject: RE: Oxitec GM mosquito trial
>
>
>
> Dear [redacted]
>
>
>
> Thank you for following up with us regarding the Oxitec Mosquito Trial in the Florida Keys. Oxitec has shared their evaluation plan with CDC, and CDC consulted with Oxitec on their planned evaluation. However, CDC is not formerly involved in any evaluation at this time. CDC is not overseeing the trial, and CDC doesn't plan to conduct any health assessments before, during, or after the trials. Unless a state health department has requested technical assistance from CDC, decisions about mosquito surveillance and control are made and implemented locally.
>
>
>
> The U.S. Environmental Protection Agency (EPA) oversees the registration of insecticides and biopesticides and studies their effectiveness and safety. The EPA approved an experimental use permit (EUP) to test Oxitec's OX5034 Aedes aegypti mosquitoes on May 1, 2020. EPA notes in their press release (https://www.epa.gov/pesticides/epa-approves-experimental-use-permit-test-innovative-biopesticide-tool-better-protect) that Oxitec is required to monitor and sample the mosquito population weekly in the treatment areas, and EPA maintains the right to cancel the EUP at any point during the 24-month period if unforeseen outcomes occur. The EUP is effective from April 30, 2020 to April 30, 2022, and you can find more information here: https://www.regulations.gov/document/EPA-HQ-OPP-2019-0274-0360.

>
>
> For more information on biopesticides and health, consult the EPA: https://www.epa.gov/pesticides/forms/contact-us-about-pesticides.
>
>
>
> Sincerely,
>
>
>
> Lyle R. Petersen, MD, MPH
>
> Director
>
> Division of Vector-Borne Diseases
>
> Centers for Disease Control and Prevention Fort Collins, CO 80521 USA
>
> Email: dvbd@cdc.gov